ClinicalTrials.gg
Not yet recruitingNCT06840522TEACHUpdated Feb 24, 2025

The Importance of Tailored Education And Device Handling for Asthmatic Patients

An observational study in Asthma, sponsored by Chiesi Hungary Ltd.. Not yet recruiting at 6 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Chiesi Hungary Ltd. (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Planned enrollment
10th of 15
250 · median 300
Started
2025
with 4 others
Observational
15 of 81
6 open now
Primary completion
2026-06
later than 2 of 10 live
Registered
73rd of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 10th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2025, is one of 15 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 73rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Significant advancements have been made in asthma medication over the past decades. Highly effective treatments are available for patients; however, both adherence and proper device usage remain below the desired levels, based on our experience and literature data. Despite the availability of numerous excellent drug-device combinations, personalized treatment for patients is still not adequately addressed.

In the present study, the aim is to improve patient compliance and educate symptomatic, partially, or uncontrolled asthma patients on the correct use of a specific inhalation device (Nexthaler). Considering the characteristics of the medication, the patient's lung function data, inhalation technique, and drug retention time can help estimate the expected lung deposition of the medication. By refining the inhalation technique under the guidance of the treating physician, it is hypothesized that the expected therapeutic effects of the medication may improve.

Read the detailed description

Eligible Patient Population:

Patients on GINA step 2-4 therapy who are partially or uncontrolled (ACT \<25) and are receiving Foster Nexthaler® therapy as per prescribing guidelines, regardless of the study. Patients on GINA step 3 therapy receive a low-dose ICS-formoterol regimen (2x1 inhalations of Foster Nexthaler® 100/6 μg), while those on GINA step 4 receive a medium-dose ICS-formoterol regimen (2x2 inhalations of Foster Nexthaler® 100/6 μg). Whenever possible, Foster Nexthaler® 100/6 μg is used as a reliever medication following the MART principles. If the treating physician opts for salbutamol (Ventolin®, Buventol®) instead, the patient may still be included in the study, provided justification is given, considering the difficulty of training with multiple inhalation devices (pMDI and DPI with different characteristics).

Study Procedures:

Lung function tests will be performed on enrolled patients. The investigating physician will evaluate the recorded spirometry curves, which will be used for computer modeling to assess pulmonary drug deposition. The spirometry curves are also useful for evaluating the patient's condition and monitoring progress.

During the study visits (V1 - enrollment, V2 - 1 month, V3 - 3 months), the following data will be recorded: patient demographics, medical history, treatment details, risk factors, medication adherence (based on prescription refills and patient self-report), and quality of life assessment. Data collection, particularly questionnaire results, will follow the daily routine of the study center.

Study Objective:

The aim is to demonstrate that patient education on using a specific inhalation device (Foster Nexthaler®), optimizing inhalation technique (prolonging breath-hold time), and the resulting increased drug deposition lead to measurable clinical benefits, improved asthma control, and higher ACT scores.

Education on inhaler use and practicing optimal inhalation techniques are expected to improve lung function, maintain adherence, and reduce the need for rescue medication.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Inhalation treatment
  • Lung deposition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Asthma patients, treated in routine clinical practice, symptomatic on previous therapy, and switched to Foster 100/6 micrograms in Nexthaler device, irrespective of study inclusion,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Physician-confirmed clinical diagnosis of asthma according to GINA guidelines
  2. Uncontrolled asthma according to the physician's clinical assessment despite the use of appropriate therapy of Step 2 or 3, according to GINA guidelines
  3. Patients who are eligible for the use of Foster Nexthaler 100/6 mcg according to the SmPC
  4. Inhaled asthma therapy was changed independent from the study to Foster Nexthaler 100/6 mcg DPI maximum 1 week prior to OR on the day of study inclusion
  5. Spirometry was performed as part of routine clinical practice
  6. Patient able to use their Foster Nexthaler device properly after education on inhaler technique
  7. Patient provided written, to study participation
  8. Patient ≥ 18 years of age

Exclusion criteria

Exclusion Criteria:

  1. Participation in any clinical trial, 30 days prior to inclusion
  2. Patient is unable to execute a spirometry test
  3. Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment.
  4. Patients with other significant diseases of the respiratory system or other organ systems that may significantly contribute to asthma symptoms (such as severe heart failure, symptomatic anaemia, functional respiratory disorders, malignant diseases etc.) according to the physician's clinical assessment.
  5. Continuous use of oral (>5 mg prednisolone/day or >4 mg methylprednisolone/day)
  6. Use of continuous oxygen therapy
  7. Use of biologics for asthma treatment
  8. All exclusion criteria listed in Foster Nexthaler 100/6 SmPC
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthma patients on GINA steps 3 and 4 receiving Foster Nexthaler treatment

    Asthma patients above the age of 18 years. Uncontrolled according to the physician's clinical assessment despite the use of appropriate therapy of Step 2 or 3, according to GINA guidelines. Patients who are eligible for the use of Foster Nexthaler 100/6 mcg according to the SmPC. Inhaled asthma therapy was changed independent from the study to Foster Nexthaler 100/6 mcg DPI maximum 1 week prior to OR on the day of study inclusion. Spirometry was performed as part of routine clinical practice . Patient able to use their Foster Nexthaler device properly after education on inhaler technique. Patient provided written, informed consent to study participation

06

What researchers measure

Primary outcomes

  1. Pulmonary deposition

    Difference of pulmonary deposition between patients performing different lengths of breath hold and it's changes after 3 months of treatment.

    Time frame: 3 months

  2. Asthma control questionnaire

    Change in asthma control questionnaire (ACQ-6) scores after 3 months of treatment between patients performing different lengths of breath hold.

    Time frame: 3 months

Secondary outcomes

  1. Asthma control

    Proportion of patients achieving improvement in asthma control at Visit 3 between patients performing different lengths of breath hold

    Time frame: 3 months

  2. Lung function

    Change in spirometry parameters: Forced expiratory volume in 1 second, Forced vital capacity and their ratio, at Visit 3, compared to the baseline between patients performing different lengths of breath hold

    Time frame: 3 months

  3. Rescue medication

    Change in the need for rescue medications at Visit 3, compared to the baseline between patients performing different lengths of breath hold

    Time frame: 3 months

  4. Adherence

    Changes in treatment adherence based on prescription filled at Visit 3, compared to the baseline between patients performing different lengths of breath hold

    Time frame: 3 months

  5. Fractional exhaled nitric oxide

    Change in fractional exhaled nitric oxide (FeNO) values at Visit 3 (count and percentage of patients with FeNO above 20 ppb) between patients performing different lengths of breath hold

    Time frame: 3 months

  6. Health related quality of life

    To assess changes in quality of life in EQ-5D-5L domains after 3 months of treatment compared to baseline. Scale on a level of five

    Time frame: 3 months

  7. Adherence self report

    To assess changes itest of adherence to inhalers questionnaire (TAI-12) after 3 months of treatment compared to baseline.

    Time frame: 3 months

07

Study locations

6 sites
  • National Korányi Institute of Pulmonology
    Budapest, Hungary
    • Ildikó Horváth, Prof. · Contact
    • Lilla Horváth, Dr. · Sub investigator
    • Balázs Juhász, Dr. · Sub investigator
    • Ildikó Horváth, Prof. · Principal investigator
    • Péter Somogyi, Dr. · Sub investigator
    • Barbara Tamás, Dr. · Sub investigator
    • Kincső Marton, Dr. · Sub investigator
  • Department of Pulmonology and Allergology, Csornai MArgit Hospital
    Csorna, Hungary
    • Zoltán Bártfai, Dr. · Contact
    • Zoltán Bártfai, Dr. · Principal investigator
  • Department of Pulmonology, Debrecen University
    Debrecen, Hungary
    • Ildikó Horváth, Prof. · Contact
    • Krisztina Kukuly, Dr. · Sub investigator
    • Tamás Kovács, Dr. · Sub investigator
    • Ildikó Horváth, Prof. · Principal investigator
  • Pulmonology Outpatient Clinic of Dunakeszi
    Dunakeszi, Hungary
    • Katalin Kontz, Dr · Contact
    • Katalin Kontz, Dr. · Principal investigator
  • Department of Pulmonology, University of Szeged
    Szeged, Hungary
    • Ádám Mihály · Contact
    • Ádám Mihály, Dr. · Principal investigator
    • Dániel Vas, Dr. · Sub investigator
  • Calvinist Pulmonology Centre
    Törökbálint, Hungary
    • Alpár Horváth, Dr. · Contact
    • Alpár Horváth, Dr · Principal investigator
    • Izolda Réti, Dr. · Sub investigator
    • Botond Havadtői, Dr. · Sub investigator
    • Norbert Ilyés, Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jun 2026, 15 months later.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 15 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Feb 21, 2025
StartEst.
Mar 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06840522
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Feb 24, 2025

Study contacts

Balázs Sánta
Contact
b.santa@chiesi.com
+36309948432

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion